Somewhere this month, a clinician will sit across from an adult with Down syndrome and a family who have read about lecanemab and donanemab, and will have to answer a question the evidence base cannot answer. The person in the chair has the most predictable form of Alzheimer's disease there is: an extra copy of chromosome 21 means an extra copy of the amyloid precursor protein gene, and a peer-reviewed perspective in Alzheimer's and Dementia last year put lifetime dementia risk in Down syndrome above 90 percent, with prevalence of 88 to 100 percent after age 65. Two drugs now exist that clear amyloid from the brain. Neither has been tested in a single person with Down syndrome in a completed trial.
That bind is the subject of a narrative review published in Alzheimer's and Dementia in April 2026 by Clíona Farrell, Fedal Saini, Mona Beidas, Natalie Ryan, Andre Strydom and Frances Wiseman, working at the UK Dementia Research Institute at University College London and at King's College London. It is a review of existing literature, not new data: the authors ran targeted PubMed searches in October 2025 and selected papers by relevance. Their conclusion is stated plainly. The blood-brain barrier and the immune system differ in people with Down syndrome, and cerebral amyloid angiopathy, amyloid laid down in the walls of brain blood vessels, is more extensive than in late-onset Alzheimer's. On that basis, they judge that side-effect risks from anti-amyloid antibodies are likely to be elevated.
The side effect in question has a bland name and a serious profile. Amyloid-related imaging abnormalities, or ARIA, come in two forms: swelling and fluid (ARIA-E) and bleeding or iron deposits (ARIA-H). In the pivotal trials in the general population, as summarised in the review, lecanemab produced ARIA-E in 12.6 percent of treated participants against 1.7 percent on placebo, and ARIA-H in 14 percent against 7.7 percent. Donanemab produced ARIA-E in 24 percent against 2.1 percent, and ARIA-H in 31.4 percent against 13.6 percent. Most cases resolve, but the review notes that some people develop headache, confusion or gait problems, and that fatal brain bleeds have occurred in rare cases. The reason amyloid in vessel walls matters is that it is a known risk factor for exactly this. The review is careful about the other side of the ledger too: the APOE e4 allele, the strongest genetic driver of ARIA, is less frequent in Down syndrome, which at a group level may pull risk the other way, and a slower titration schedule cut donanemab ARIA-E from 23.7 percent to 13.7 percent at 24 weeks.
The most concrete piece of evidence sits underneath all of this, and it comes from a microscope rather than a clinic. In JAMA Neurology, published online on 19 August 2024, Lei Liu, Elizabeth Head and colleagues applied lecanemab to postmortem brain tissue from 15 people with Down syndrome, aged 43 to 68 (mean 56.6, eight of them female). The antibody labelled amyloid plaques in all 15 cases, which is what you would want: target engagement. It also bound extensively to the amyloid in brain blood vessels. This was tissue, not people, and it cannot tell anyone how often ARIA would actually happen, how severe it would be, or whether the drug would slow decline. What it does is give a physical picture of where the antibody would go.
Here is the gap the review is really about. The licensed indications for these drugs are defined by disease stage and confirmed amyloid, not by the cause of the amyloid; the exclusion of people with Down syndrome lives in expert guidance rather than in the licence. The 2023 appropriate use recommendations for lecanemab, written by James Cummings and colleagues, stated that because of increased cerebral amyloid angiopathy, patients with Down syndrome should be excluded from treatment. The 2026 review pushes back on the ethics of leaving it there: blanket exclusion of a group who develop this disease more predictably than anyone else is not a neutral act either, and the authors argue the answer is research designed for this population rather than an indefinite pause. Reporting at the time of the tissue study noted that the drug companies said they had not explicitly excluded people with Down syndrome from their trials; the age thresholds and design largely did it for them.
Something is finally moving. ALADDIN, registered as NCT06911944 and sponsored by the University of Southern California through the Alzheimer's Clinical Trials Consortium for Down Syndrome, is a randomised, double-blind, placebo-controlled phase 4 dose-escalation study of donanemab in adults with Down syndrome aged 35 to 50 who have elevated amyloid on a brain scan. The registry entry, verified in May 2026, lists it as not yet recruiting, with an estimated start date of 1 August 2026 and estimated completion in December 2028. For a family sitting in a clinic today, that is the honest shape of things: a biological argument that the risk is higher, a tissue study that shows why, an ethical argument that exclusion is not a safe default, and the first real answer still more than two years away.